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Abstract
Nucleotide-competing reverse transcriptase inhibitors were shown to bind reversibly to the nucleotide-
binding site of the reverse transcriptase (RT) enzyme of human immunodeficiency virus type 1 (HIV-1).
Here, we show that the presence of ATP can enhance the inhibitory effects of the prototype compound
INDOPY-1. We employed a combination of cell-free and cell-based assays to shed light on the underlying
molecular mechanism. Binding studies and site-specific footprinting experiments demonstrate the existence
of a stable quaternary complex with HIV-1 RT, its nucleic acid substrate, INDOPY-1, and ATP. The
complex is frozen in the post-translocational state that usually accommodates the incoming nucleotide
substrate. Structure-activity relationship studies show that both the base and the phosphate moieties of ATP
are elements that play important roles in enhancing the inhibitory effects of INDOPY-1. In vitro
susceptibility measurements with mutant viruses containing amino acid substitutions K70G, V75T, L228R,
and K219R in the putative ATP binding pocket revealed unexpectedly a hypersusceptible phenotype with
respect to INDOPY-1. The same mutational cluster was previously shown to reduce susceptibility to the
pyrophosphate analog phosphonoformic acid. However, in the absence of INDOPY-1, ATP can bind and
act as a pyrophosphate donor under conditions that favor formation of the pre-translocated RT complex.
We therefore conclude that the mutant enzyme facilitates simultaneous binding of INDOPY-1 and ATP to
the post-translocated complex. Based on these data, we propose a model in which the bound ATP traps the
inhibitor, which, in turn, compromises its dissociation.
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Introduction
The reverse transcriptase (RT)  of human immunodeficiency virus type 1 (HIV-1) is an RNA- and
DNA-dependent DNA polymerase that remains a prime target for antiretroviral intervention. The two
approved classes of RT inhibitors are nucleoside analog (NRTI) and non-nucleoside analog (NNRTI) RT
inhibitors. Phosphorylated NRTIs compete with natural deoxynucleoside triphosphates (dNTPs), bind to the
polymerase active site, and cause chain termination of the growing DNA strand. Binding of NNRTIs to a
hydrophobic pocket near the polymerase active site results in inhibition of nucleotide incorporation without
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Materials
Single Nucleotide Incorporation Assay
directly competing with the substrate (1–5).
Indolopyridone-derived compounds (6, 7) represent a novel, investigational class of RT inhibitors that
suppress DNA polymerization through a mechanism that is distinct from both NRTIs and NNRTIs.
INDOPY-1 (Fig. 1), the prototype compound of this class, was shown to be active against NNRTI-resistant
HIV strains (6, 7). However, certain NRTI resistance-conferring mutations in the vicinity of the polymerase
active site confer resistance to this inhibitor (6, 7). Mutation M184V that confers high level resistance to the
NRTI lamivudine (3TC) was shown to reduce susceptibility to INDOPY-1. This mutation discriminates
against both inhibitors at the level of binding (8–11). In contrast, Y115F in HIV-1 RT appears to enhance
nucleotide binding at the cost of inhibitor binding. As such, both mutations together amplify the level of
resistance. These findings represent strong evidence to show that despite distinct structures, INDOPY-1
may share some common properties with NRTIs.
Different classes of RT inhibitors can bind to different conformations of the RT·nucleic acid complex.
Following incorporation of the nucleotide substrate and release of the pyrophosphate (PPi) product, the RT
enzyme can rapidly shuttle between pre- and post-translocational states (12–17). Footprinting studies
revealed that NRTIs and natural nucleoside triphosphates (dNTPs) can only bind to and trap the RT
complex in its post-translocated state (13). INDOPY-1 behaves identically in these assays (6). Conversely,
the PPi analog foscarnet (phosphonoformic acid, PFA) traps the complex in the pre-translocational state
(15). However, unlike NRTIs and dNTPs, INDOPY-1 does not require the templated nucleotide for base
pairing. It rather seems that the compound recognizes the ultimate base pair. “Hot spots” for inhibition of
DNA synthesis are seen when the primer 3′ terminus contains a pyrimidine base (6, 7). Together, these data
suggest that the binding sites for INDOPY-1 and the dNTP substrate partially overlap. Hence, RT inhibitors
with the aforementioned properties are collectively referred to as “nucleotide-competing RT inhibitors”
(NcRTIs) (8, 18).
In this study, we demonstrate that the presence of adenosine triphosphate (ATP) can enhance the inhibitory
effects of INDOPY-1. Previous studies have shown that ATP can also act as a PPi donor that promotes
excision of incorporated NRTIs (19). This reaction provides an important mechanism for resistance to this
class of inhibitors, in particular to zidovudine (AZT). However, in this context, ATP traps the
pre-translocated RT complex (20). Here, we utilized a combination of cell-based and cell-free assays to
characterize the mode of binding of ATP in conjunction with INDOPY-1. We demonstrate that ATP and
INDOPY-1 can form a quaternary complex with RT and its nucleic acid substrate. These findings point to a
highly flexible ATP-binding site that can accommodate this ligand in various orientations in both pre- and
post-translocational conformations. We conclude that the bound ATP compromises dissociation of
INDOPY-1 from a post-translocated complex.
EXPERIMENTAL PROCEDURES
The heterodimeric (p66/p51) HIV-1 RT enzyme was expressed in Escherichia coli and purified as
described previously (21). Site-directed mutagenesis was performed using the Stratagene QuikChange
procedure. WT RT refers to the wild-type enzyme (HXB2 strain). TAM1 RT contains mutations M41L,
D67N, L210W, and T215Y. TAM2 RT contains mutations D67N, K70R, T215F, and K219Q. “Remodeled
TAMs” RT harbors mutations K70G, V75T, L228R, and K219R. Oligonucleotides were chemically
synthesized and purchased from IDT with the exception of RNA template PBS-250 that was synthesized
through in vitro transcription with T7 RNA polymerase (22). The DNA primer was either synthesized with
a fluorescent Cy5 or Alexa488 label at its 5′-end or P-radiolabeled with [γ- ]ATP and T4 polynucleotide
kinase (Fermentas) (13). Alexa555 quencher dUTP was purchased from Invitrogen. The RT inhibitor
INDOPY-1 was obtained through the AIDS Research and Reference Reagent Program (Division of AIDS
NIAID, National Institutes of Health), and Tibotec BVBA is the reagent contributor. Natural and modified
nucleotides were purchased from Fermentas and TriLink, respectively (chemical structures are provided in
supplemental Fig. 1).
A 3-fold excess of DNA template (C1-A,
5′-GTAACTAGAGATCCCTCAGACCCTTTTAGTCAGAAT) was hybridized to 50 nM of a fluorescently
labeled DNA primer (8aT_Cy5, 5′-Cy5-TTCTGACTAAAAGGGTCTGAGGGAT). DNA·RNA hybrids
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In Silico Docking of INDOPY-1 and ATP
were formed in a buffer containing 50 mM Tris-HCl, pH 7.8, and 50 mM NaCl. Samples were heated to 95
°C for 3 min followed by a gradual decrease to room temperature. The hybrid was then incubated with 50
nM HIV-1 RT in a buffer containing 50 mM Tris-HCl, pH 7.8, 50 mM NaCl, as well as varying amounts of
ATP and increasing concentrations of INDOPY-1 (0–18 µM). Nucleotide incorporation was initiated with
the addition of 6 mM MgCl  and 100 nM dCTP at 37 °C and was allowed to proceed for 5 min. Samples
were resolved on a 12% denaturing polyacrylamide gel and analyzed with a phosphorimager instrument
(Amersham Biosciences) using Quantity One and ImageQuant software.
A 2-fold molar excess of PBS-250 RNA template
was hybridized to 50 nM of 5′-radiolabeled PBS-28 DNA primer
(5′-CTTTCAGGTCCCTGTTCGGGCGCCACTG). The hybrid was then incubated with 125 nM RT in a
buffer containing 50 mM Tris-HCl, pH 7.8, 50 mM NaCl, and 10 µM of each dATP, dTTP, dGTP, and dCTP.
DNA synthesis was initiated by the addition of 6 mM MgCl  in the absence or presence of inhibitor and
NTPs at 37 °C. DNA synthesis was stopped at defined time points by the addition of formamide loading
dye. Samples were subsequently resolved on a 12% denaturing polyacrylamide gel. Similar conditions were
employed for monitoring AZT-MP excision whereby 50 nM DNA primer·template were incubated with 250
nM RT and 10 µM AZP-TP in the presence of 0.5 µM dNTPs and 3.5 mM pyrophosphatase-treated ATP.
Reactions were preincubated at 37 °C for 5 min and then initiated with 6 mM MgCl . AZT-MP excision and
DNA synthesis rescue was measured at various time points up to 90 min. DNA synthesis was visualized on
12% denaturing polyacrylamide gels.
50 nM DNA·DNA hybrid (primer, PPT-24Cy5 5′-Cy5-
ACTTTTTAAAAGAAAAGGGGGGAT; template, PPT-57
5′-CGTTGGGAGTGAATTAGCCCTTCCAGTCCCCCCTTTTCTTTTAAAAAGTGGCTAAGA) was
incubated with 5-fold molar excess of WT RT enzyme in the presence of 50 mM Tris-HCl, pH 7.8, 50 mM
NaCl, and increasing concentrations of INDOPY-1 (0–4 µM). The stability of enzyme binding to the nucleic
acid substrate was assessed in the absence or presence of ATP by the addition of 1.5 µg/µl heparin trap.
Samples were incubated for 15 min at 37 °C and visualized on a nondenaturing 6% polyacrylamide gel.
40 nM of the DNA template containing an Alexa-488 fluorescent dye at the 5′ terminus
(5′-Alexa488-AGTCCCCCCTTTTCTTTTAAAAAGTGGCTAAGA) was hybridized to a 3-fold molar
excess of DNA primer (5′-TTAAAAGAAAAGGGGGG). The hybrid was then incubated with 1 nM RT in a
buffer containing 50 mM Tris-HCl, pH 7.8, 80 mM KCl, 0.025% CHAPS, 6 mM MgCl  0.1 mM EGTA, and
1 mM DTT. 200 nM of nucleotide mix containing dATP, dCTP, dGTP, and a modified dUTP were added
along with INDOPY-1 (0–30 µM). The modified dUTP contains an Alexa555 quencher, which upon
incorporation quenches excitation by Alexa488 present on the DNA template (23). The signal was
monitored over a period of 60 min using SPECTRAmax M5 fluorometer where reductions in Alexa488
emission signals are indicative of increased DNA polymerization.
Translocation of the enzyme relative to the nucleic acid substrate was monitored
using Fe  site-specific footprinting techniques as described previously (13, 24). Briefly, 150 nM of primer
(PPT-20 5′-TTAAAAGAAAAGGGGGGACT) was hybridized to 50 nM DNA template PPT-57
(5′-CGTTGGGAGTGAATTAGCCCTTCCAGTCCCCCCTTTTCTTTTAAAAGTGGCTAAGA) containing
a radiolabel at the 5′ terminus. The DNA hybrid was then incubated with 750 nM RT (WT or mutant) in a
buffer containing 120 mM sodium cacodylate, pH 7, 20 mM NaCl, and 10 mM MgCl  with and without 1
mM ATP as indicated. The samples were then incubated with a concentration gradient of INDOPY-1 and
treated with Fe  after a 10-min incubation at 37 °C. Samples were resolved on a 12% denaturing
polyacrylamide gel.
Standard deviations for all datasets were calculated through GraphPad Prism software. Briefly, the sum of
the square of the difference between each value and the mean was divided by n − 1. The square root of this
value represents the standard deviation as calculated by the software.
Binding models were generated using the crystal structure of the
HIV-1 RT/chain-terminated primer·template·dTTP ternary complex (PDB code 1RTD) (25). The dTTP
substrate present at the active site of the 1RTD structure was removed prior to INDOPY-1 docking. ATP
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was subsequently docked to the structural model with INDOPY-1 present in the active site. The structure of
INDOPY-1 was constructed in ChemDraw (CambridgeSoft Corp.), energy-minimized for 100 cycles under
default parameters using Chimera, and saved as a PDB file. The structures of the protein and the small
molecule were prepared for docking using AutoDockTools 1.5.4. Subsequently, the docking was performed
using AutoDock Vina. Modeling of ATP binding in the context of INDOPY-1 was performed using the same
protein crystal structure as above; however, the coordinates for the best candidate pose for INDOPY-1
binding were this time introduced into the PDB file of the protein. Molecular graphics images were
produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco (supported by National Institutes of Health Grant
P41 RR-01081).
The N terminus of RT (amino acids 25–314) of HIV-1 clones containing
the TAM1, TAM2, and remodeled TAM mutations (26) were amplified, digested, and ligated using the
previously described NRT-vector system (27). Clones were verified by sequence analysis. To generate
recombinant viruses, RT molecular clones were transfected in 293T cells. For this, 5–6 × 10  293 T cells
were seeded the day prior to transfection to achieve 90–95% confluence on the day of transfection. For
transfection, 10 µg of plasmid DNA and Lipofectamine 2000 (Invitrogen) were used according to the
manufacturer's protocol. Two days after transfection, recombinant virus was harvested. 50% tissue culture
infective dose was determined by end point dilution in MT2 cells or human donor peripheral blood
mononuclear cells (PBMCs).
Drug susceptibility was determined by a multiple cycle cell-killing assay (28).
MT-2 cells (5 × 10  in 200 µl of RPMI 1640 medium and 10% FBS per well) were plated in 96-well
microplates. Recombinant virus and reference virus were inoculated for 5 days on a single 96-well plate in
the presence of drug dilutions. All viruses were inoculated at multiple multiplicities of infection to adjust for
any differences in viral replication capacity (RC). Fold change values were calculated by dividing the mean
50% effective concentration for a recombinant virus by that of the HXB2 reference strain. Fold changes are
averages of at least two separate experiments. Drug susceptibility was also analyzed in donor PBMCs.
Here, activated PBMCs were infected with a recombinant virus or reference strain using a multiplicity of
infection of 0.001 (PBMC titration) incubated for 2 h at 37 °C, after which cells were washed twice.
Subsequently, 0.2 × 10  cells/well were plated into a 96-well plate with increasing drug concentrations. p24
was analyzed on days 0 and 7.
RESULTS
We monitored single nucleotide incorporations
with purified HIV-1 RT in the presence of increasing concentrations of INDOPY-1. This assay revealed an
IC  value of 2.5 µM in the absence of ATP (Fig. 2A). In the presence of physiologically relevant
concentrations of 3 mM ATP (29), we determined an IC  value of 0.25 µM. IC  values for INDOPY-1
are shown as a function of increasing concentrations of ATP, which demonstrates a dose-dependent effect
of the enhancer molecule.
We next asked whether the enhancement of inhibition was specific to the nucleotide base of ATP. To
address this issue, we monitored multiple nucleotide incorporations on a heteropolymeric template. In the
absence of inhibitor, the full-length DNA product appeared within 7 min (Fig. 2B). Saturating
concentrations of 6 µM INDOPY-1 reduced the amount of DNA product observed over the same period of
time. When DNA synthesis was compared in the presence of INDOPY-1 and 3 mM ATP, UTP, GTP, or CTP,
we found that ATP showed the strongest enhancement of inhibition. GTP showed subtle but visible
increases in inhibition, whereas pyrimidines UTP and CTP do not seem to act as enhancers. In the absence
of INDOPY-1, the presence of NTPs showed only subtle effects on DNA synthesis (data not shown). These
findings suggest that the base moiety represents an important structural element in enhancing the inhibitory
effects of NcRTIs.
We monitored inhibition of DNA synthesis and its
enhancement in the presence of derivatives of ATP with modifications in base, sugar, and phosphate
moieties, respectively (for structural details, see supplemental Fig. 1). The loss of the 6-amino group of the
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purine (benzimidazole and 2-aminopurine), as well as modifications at this position (N6-methyl) severely
compromised the enhancement of inhibition (Fig. 3A). Note that in contrast to 2-aminopurine, the related
GTP and 2-amino-ATP retain their ability to increase inhibition (Figs. 2B and 3B). Hence, it appears that
the presence of a hydrogen bond donor or acceptor is essential at position 6. Modifications at the smaller
ring did not show any significant effect (Fig. 3B). In the absence of INDOPY-1, each of these compounds
had no significant effect on polymerization under the same conditions (data not shown).
We also studied several ATP derivatives with modifications primarily at the 2′- and/or 3′-position of the
sugar ring. Neither of these compounds showed any significant reductions in enhancement of inhibition.
Modifications at the phosphate moiety show a stronger effect. Whereas 1-thio-ATP retains the ability to
enhance the inhibitory effect of INDOPY-1, marked decreases are seen in the following order: ATP > ADP
> AMP > A (Fig. 3B). Taken together, an intact triphosphate moiety together with a hydrogen bond donor
or acceptor at position 6 of the purine base seem to be important structural elements that facilitate binding
of the ATP enhancer.
The effect of ATP on
INDOPY-1-mediated inhibition of DNA synthesis suggest the formation of a quaternary complex. We
employed band shift experiments to test this hypothesis. In this assay, INDOPY-1 can bind to and stabilize
the RT·DNA·DNA complex (Fig. 4A) (6, 8). The resulting ternary complex is resistant to the challenge with
heparin that traps the dissociated enzymes. Increasing concentrations of INDOPY-1 correlate with an
increased stability of the complex (Fig. 4A). In the absence of INDOPY-1, ATP alone has no effect on
complex stabilization. In the presence of ATP, stable complex formation is observed at lower concentrations
of INDOPY-1. The K  value for INDOPY-1 is 216.5 nM (±56.2). In the presence of ATP, this value is
decreased to 15.4 nM (±1.8) (Fig. 4B). Thus, the enhancing effect of ATP on INDOPY-1-mediated
inhibition of RT correlates with the formation of a stable quaternary complex.
ATP is able to act as a PPi donor that removes incorporated NRTIs from the 3′-end of
the primer. Like PFA, ATP binds to and exerts this function through the pre-translocational complex (13,
16, 17, 19, 20, 30–33). However, INDOPY-1 was shown to trap the post-translocated complex (6). To
address this apparent disconnect, we examined the potency of INDOPY-1 in the context of a series of RT
mutations that are known to affect binding of ATP. Mutations that confer resistance to the NRTI AZT,
referred to as thymidine-associated mutations (TAM1 or TAM2), facilitate binding of ATP in an orientation
that promotes excision (19, 20, 31, 34, 35). We therefore determined EC  values for INDOPY-1, in MT-2
cells in the presence of HIV-1 virus containing either TAM1 (M41L, D67N, L210W, and T215Y) or TAM2
(D67N, K70R, T215F, and K219Q) mutational clusters (Table 1). TAM1 does not affect susceptibility to
INDOPY-1, whereas TAM2 appears to confer low levels of resistance to the inhibitor (Table 1). We have
also tested a mutational cluster, referred to as remodeled TAMs (K70G, V75T, L228R, and K219R) (36).
This pattern emerges in NRTI experienced patients who are infected with TAM-containing HIV variants
prior to PFA salvage therapy. Remodeled TAMs were shown to reduce resistance to AZT and confer
resistance to PFA. Here, we confirmed this phenotype in biochemical assays. Whereas TAM1 and TAM2
show subtle increases in sensitivity to PFA, the RT enzyme containing remodeled TAMs is only inhibited at
markedly higher concentrations of PFA (Fig. 5). This effect is in part mediated through K70G, which is in
agreement with previous reports that analyzed K70G in a different mutational context (37, 38). Moreover,
DNA synthesis in the presence of AZT-TP and the PPi donor ATP showed reduced excision of the
incorporated chain terminator when remodeled TAM was compared with TAM1- or TAM2-containing RT
enzymes (Fig. 6). Hence, remodeled TAMs may directly affect the binding site of ATP, although several
other mutations also confer resistance to PFA (39–42). As a control, we also measured susceptibility to
these compounds in cell culture, and in agreement with Mathiesen et al. (36), remodeled TAMs conferred
resistance to PFA, whereas decreased susceptibility to AZT was only observed with strains harboring TAM1
and TAM2 (Table 1). Remodeled TAMs cause hypersusceptibility to INDOPY-1 (0.2-fold change in EC
when compared with WT HIV-1). The presence of remodeled TAMs in the purified RT also caused a
decrease in IC  values for INDOPY-1, which is in agreement with the cell culture data (Table 2). This
effect is more pronounced in the presence of ATP, suggesting that this mutational cluster can promote
binding of INDOPY-1 and ATP, respectively (Table 2).
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An improved binding of INDOPY-1 and ATP against a backbone of remodeled TAMs is difficult to
reconcile with the findings that these mutations diminish resistance to AZT (36). However, the excision-
competent complex with ATP exists in the pre-translocated conformation, whereas INDOPY-1 traps the
post-translocated complex. To establish that the quaternary complex with INDOPY-1 and ATP remains in
the post-translocated conformation, we performed site-specific footprinting experiments that allow us to
distinguish between both pre- and post-translocational states (Fig. 7A) (13, 15). As the concentration of
INDOPY-1 increases, the cleavage pattern with WT RT is shifting from pre- to post-translocation, as
described previously (6). Here, the data further show that the presence of ATP lowers the concentration of
INDOPY-1 required to cause a complete shift toward post-translocation (Fig. 7). These findings
demonstrate that ATP indeed stabilizes the complex with INDOPY-1 in the post-translocated conformation.
The effect of INDOPY-1 on the translocational state is slightly increased against a backbone of remodeled
TAMs (Fig. 7, A and B), which is in agreement with the hypersusceptible phenotype.
Together, these data suggest that remodeled TAMs confer a post-translocational bias that reduces PFA
susceptibility and ATP-dependent excision of AZT-MP, both of which occur in the pre-translocated state.
At the same time, the increased access to the post-translocated complex results in INDOPY-1
hypersusceptibility.
DISCUSSION
NcRTIs, like the prototype compound INDOPY-1, represent a novel class of small molecules that inhibit
HIV-1 RT at concentrations in the submicromolar range. Enzyme kinetics and in vitro selection experiments
provided strong evidence to show that the binding site of INDOPY-1 overlaps with the nucleotide-binding
site (6, 8). Site-specific footprinting experiments further revealed that the inhibitor, like the natural dNTP
substrate, traps the RT complex in its post-translocational state (6). Here, we show that the presence of ATP
can significantly enhance the inhibitory effect of INDOPY-1. We studied the underlying molecular
mechanism with particular focus on the binding mode and orientation of the ATP enhancer molecule.
A limited structure-activity relationship analysis revealed that the phosphate and base moieties of ATP are
required to promote this effect. The enhancement of inhibition decreases in the following order: ATP >
ADP > AMP. Pyrimidines UTP and CTP are inactive, whereas purines ATP and, to a lesser extent, GTP are
active enhancer molecules. In attempts to provide a better understanding of these findings, we also included
several ATP derivatives in this analysis. The data suggest that the presence of a hydrogen bond donor or
acceptor at position 6 of the purine ring system is crucial for enhancing NcRTI-mediated inhibition. The
specificity for purine analogs also points to a unique feature of the ATP-binding site that is distinct from the
dNTP-binding site, which needs to accommodate both purines and pyrimidines. These results are not
unexpected, given that ribonucleotides bind to this site with low affinity due to a steric conflict between the
2′-OH group and residue Tyr-115 in HIV-1 RT (43, 44). Moreover, INDOPY-1 competes with dNTP
substrates, which suggests that the nucleotide-binding site is at least in part occupied by the inhibitor.
Like the natural dNTP substrate, INDOPY-1 can form a stable complex with HIV-1 RT and its
primer·template substrate (6, 8, 45). These complexes are resistant to challenges with an enzyme trap, such
as heparin. Crystal structures of HIV-1 RT with and without a bound dNTP substrate have shown that the
fingers subdomain close down and trap the incoming dNTP, which stabilizes the complex (25, 46). A similar
scenario has been postulated for the ternary complex with INDOPY-1 (6, 8), although the particular
conformation of the “closed” structure likely differs from the ternary RT·DNA·DNA·dNTP complex. Here,
we show that concentrations of ATP in the low millimolar range can reduce the amount of INDOPY-1
required to stabilize the RT complex. Together, these data provide strong evidence to suggest that RT, its
nucleic acid substrate, the inhibitor, and the ATP enhancer molecule form a stable quaternary complex.
Binding of ATP to HIV-1 RT has previously been demonstrated in a different context (19, 20, 35). ATP can
bind in an orientation that facilitates the excision of the ultimate nucleotide from the primer terminus. This
reaction provides an important mechanism for resistance to NRTIs. TAM1 or TAM2 mutational clusters
were shown to increase rates of excision of incorporated AZT-MP, and other inhibitors of this class (19).
Structures that contain the dinucleotide tetraphosphate product suggest that the resistance-conferring
mutations can affect the orientation of the base moiety of the bound ATP thereby facilitating binding and its
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Model for INDOPY-1 and ATP Binding to the Polymerase Active Site of HIV-1 RT
function as a PPi donor (20). Site-specific footprinting and crystal structures of a related polymerase have
shown that the PPi analog PFA stabilizes the pre-translocational conformation though closure of the fingers
subdomain (15, 47). By contrast, INDOPY-1 traps the post-translocational state, which raised the question
whether ATP can bind to both translocational states of the RT complex. Our footprinting experiments
provide strong support for the notion that the quaternary complex with INDOPY-1 and ATP is indeed
stabilized in the post-translocational state.
To provide a more detailed picture of the ATP binding mode and orientation, we conducted in vitro
susceptibility measurements with TAM1 (M41L, D67N, L210W, and T215Y) and TAM2 (D67N, K70R,
T215F, and K219Q) and the remodeled TAMs cluster that contains mutations K70G, V75T, L228R, and
K219R. Given that TAM1 and TAM2 confer resistance to AZT and facilitate ATP binding, one would
expect increases in susceptibility to INDOPY-1. However, TAM1 does not appear to show any significant
effect, and TAM2 shows subtle decreases in INDOPY-1 susceptibility. Conversely, given that remodeled
TAMs reduce resistance to AZT and increase resistance to PFA (36), one would expect decreases in
susceptibility to INDOPY-1. However, in this case we observed a hypersusceptible phenotype, and
biochemical studies show that the mutations increase the effects of both INDOPY-1 and ATP. A possible
explanation is that remodeled TAMs can shift the translocational equilibrium toward post-translocation,
which facilitates binding of INDOPY-1. Binding of ATP and PFA to the pre-translocated conformation is at
the same time reduced under these circumstances. Essentially, the diminished excision of AZT by
remodeled TAMs indicates that binding of ATP to the pre-translocated complex is compromised. This effect
passively promotes binding of ATP instead to the post-translocated state of the enzyme to stabilize a
quaternary complex with INDOPY. This model helps to reconcile the apparent contradiction of
ATP-mediated enhancement of INDOPY-1 for remodeled TAMs and diminished resistance to AZT for the
same enzyme. In this context it is also important to note that TAM enzymes show the opposite effect on the
translocational equilibrium and confer a pre-translocational bias (48).
We employed in silico
approaches in attempts to identify possible binding pockets for INDOPY-1 and its ATP enhancer. We
docked a flexible structure of INDOPY-1 to the RT crystal structure whereby the crystallized dTTP
substrate was removed (Fig. 8). To validate our docking strategy, we redocked dTTP back into the
polymerase active site and confirmed a high degree of similarity with the original crystal structure. In our
model, INDOPY-1 binds to the nucleotide-binding site of a post-translocated complex. An important feature
of this model is that the benzene ring of the inhibitor can stack with the ultimate base of the primer (Fig. 8
A). Binding of INDOPY-1 is severely compromised with an abasic residue at the primer terminus (data not
shown), which is consistent with this model. The nitro group of the benzene ring is positioned within close
proximity to residues Met-184 and Tyr-115, and changes at these positions are associated with resistance to
this compound (Fig. 8B). Finally, the methyl group present on the pyrrole ring appears to protrude into the
“unoccupied pocket” that exists between the fingers and the thumb subdomains of HIV-1 RT (Fig. 8, C and
D).
We next docked ATP to the model of the ternary RT·DNA·DNA·INDOPY-1 complex (Fig. 8, C–E). ATP
appears to bind in an orientation that is similar to the excision complex (20), although the two complexes
exist in post- and pre-translocational states, respectively. The phosphate moiety of ATP interacts with the
same residues as seen with the crystal structure of ATP bound to RT (20), although the base of ATP bends
toward the thumb subdomain of RT and the sugar backbone of the DNA·DNA substrate. Consistent with
our structure-activity relationship data, the amino group at position 6 of ATP makes possible contacts with
other residues in the quaternary complex (Fig. 8, C–E). Finally, amino acid residues that are mutated as part
of remodeled TAMs are in close proximity to the phosphate and base moiety of the docked ATP (Fig. 8E).
In summary, according to this model, ATP can bind to the post-translocational state with INDOPY-1 bound
at the active site (Fig. 8, C–E). It is possible that both ligands ATP and INDOPY-1 stabilize the closed
complex more effectively. However, it should be noted that this docking model does not reflect the intrinsic
flexibility of the fingers and thumb subdomains. As such, crystallographic data are warranted to delineate
subtle differences in subdomain movements in the context of INDOPY-1/ATP versus dNTP binding.
Overall, the results of this study point to a highly flexible ATP-binding site of HIV-1 RT. Although previous
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studies have described and characterized binding of ATP to the pre-translocated complex as a PPi donor,
this work describes its binding to the post-translocated complex as an enhancer of the inhibitory effects of
INDOPY-1. Together, the data identify a new binding pocket for small molecule inhibitors that can be
exploited in drug discovery and development efforts to improve the properties of NcRTIs.
Acknowledgment
Anick Auger is acknowledged for excellent technical assistance.
This work was supported in part by the Canadian Institutes of Health Research, Tibotec, and Netherlands
Organisation for Scientific Research VIDI Grant 91796349.
This article contains supplemental Fig. 1.
The abbreviations used are:
RT reverse transcriptase
NcRTI nucleotide-competing RT inhibitor
PFA phosphonoformic acid
PBMC peripheral blood mononuclear cell
PPi pyrophosphate
AZT zidovudine
AZT-MP AZT-monophosphate
AZT-TP AZT-triphosphate
PDB Protein Data Bank
NRTI nucleoside analog RT inhibitor
NNRTI non-nucleoside RT inhibitor
dNTP deoxynucleotide triphosphate
NTP ribonucleotide triphosphate.
REFERENCES
1. Basavapathruni A., Anderson K. S. (2007) Reverse transcription of the HIV-1 pandemic. FASEB J. 21,
3795–3808 [PubMed: 17639073]
2. Götte M. (2004) Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.
Expert Rev. Anti-infect Ther. 2, 707–716 [PubMed: 15482234]
3. Menéndez-Arias L. (2008) Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse
transcriptase. Virus Res. 134, 124–146 [PubMed: 18272247]
4. Sarafianos S. G., Marchand B., Das K., Himmel D. M., Parniak M. A., Hughes S. H., Arnold E. (2009)
Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and
inhibition. J. Mol. Biol. 385, 693–713 [PMCID: PMC2881421] [PubMed: 19022262]
5. Sluis-Cremer N., Tachedjian G. (2008) Mechanisms of inhibition of HIV replication by non-nucleoside
reverse transcriptase inhibitors. Virus Res. 134, 147–156 [PMCID: PMC2745993] [PubMed: 18372072]
6. Jochmans D., Deval J., Kesteleyn B., Van Marck H., Bettens E., De Baere I., Dehertogh P., Ivens T., Van
Ginderen M., Van Schoubroeck B., Ehteshami M., Wigerinck P., Götte M., Hertogs K. (2006)
Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of
action. J. Virol. 80, 12283–12292 [PMCID: PMC1676280] [PubMed: 17020946]
7. Zhang Z., Walker M., Xu W., Shim J. H., Girardet J. L., Hamatake R. K., Hong Z. (2006) Novel
nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency
virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 50, 2772–2781 [PMCID: PMC1538665]
[PubMed: 16870771]
8. Ehteshami M., Scarth B. J., Tchesnokov E. P., Dash C., Le Grice S. F., Hallenberger S., Jochmans D.,
Götte M. (2008) Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against
“nucleotide-competing reverse transcriptase inhibitors.” J. Biol. Chem. 283, 29904–29911
*
4
Formation of a Quaternary Complex of HIV-1 Reverse Transcriptase wit... http://www-ncbi-nlm-nih-gov.kuleuven.ezproxy.kuleuven.be/pmc/articl...
8 van 23 10/02/2016 9:19
[PMCID: PMC2573056] [PubMed: 18728003]
9. Feng J. Y., Anderson K. S. (1999) Mechanistic studies examining the efficiency and fidelity of DNA
synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 38, 9440–9448
[PubMed: 10413520]
10. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. (1993) Rapid in vitro selection of human
immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region
of reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 90, 5653–5656 [PMCID: PMC46779]
[PubMed: 7685907]
11. Wainberg M. A., Hsu M., Gu Z., Borkow G., Parniak M. A. (1996) Effectiveness of 3TC in HIV clinical
trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10,
S3–S10 [PubMed: 9030390]
12. Götte M. (2006) Effects of nucleotides and nucleotide analogue inhibitors of HIV-1 reverse
transcriptase in a ratchet model of polymerase translocation. Curr. Pharm. Des. 12, 1867–1877
[PubMed: 16724953]
13. Marchand B., Götte M. (2003) Site-specific footprinting reveals differences in the translocation status
of HIV-1 reverse transcriptase. Implications for polymerase translocation and drug resistance. J. Biol.
Chem. 278, 35362–35372 [PubMed: 12819205]
14. Marchand B., Götte M. (2004) Impact of the translocational equilibrium of HIV-1 reverse transcriptase
on the efficiency of mismatch extensions and the excision of mispaired nucleotides. Int. J. Biochem. Cell
Biol. 36, 1823–1835 [PubMed: 15183347]
15. Marchand B., Tchesnokov E. P., Götte M. (2007) The pyrophosphate analogue foscarnet traps the
pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase
translocation. J. Biol. Chem. 282, 3337–3346 [PubMed: 17145704]
16. Marchand B., White K. L., Ly J. K., Margot N. A., Wang R., McDermott M., Miller M. D., Götte M.
(2007) Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on
the efficiency of excision of tenofovir. Antimicrob. Agents Chemother. 51, 2911–2919
[PMCID: PMC1932533] [PubMed: 17517852]
17. Sarafianos S. G., Clark A. D., Jr., Tuske S., Squire C. J., Das K., Sheng D., Ilankumaran P., Ramesha A.
R., Kroth H., Sayer J. M., Jerina D. M., Boyer P. L., Hughes S. H., Arnold E. (2003) Trapping HIV-1 reverse
transcriptase before and after translocation on DNA. J. Biol. Chem. 278, 16280–16288
[PubMed: 12554739]
18. Jochmans D. (2008) Novel HIV-1 reverse transcriptase inhibitors. Virus Res. 134, 171–185
[PubMed: 18308412]
19. Meyer P. R., Matsuura S. E., Mian A. M., So A. G., Scott W. A. (1999) A mechanism of AZT resistance:
an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4,
35–43 [PubMed: 10445025]
20. Tu X., Das K., Han Q., Bauman J. D., Clark A. D., Jr., Hou X., Frenkel Y. V., Gaffney B. L., Jones R.
A., Boyer P. L., Hughes S. H., Sarafianos S. G., Arnold E. (2010) Structural basis of HIV-1 resistance to
AZT by excision. Nat. Struct. Mol. Biol. 17, 1202–1209 [PMCID: PMC2987654] [PubMed: 20852643]
21. Le Grice S. F., Grüninger-Leitch F. (1990) Rapid purification of homodimer and heterodimer HIV-1
reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187, 307–314
[PubMed: 1688798]
22. Arts E. J., Li X., Gu Z., Kleiman L., Parniak M. A., Wainberg M. A. (1994) Comparison of
deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in
vitro reverse transcription/template-switching reaction. J. Biol. Chem. 269, 14672–14680
[PubMed: 7514178]
Formation of a Quaternary Complex of HIV-1 Reverse Transcriptase wit... http://www-ncbi-nlm-nih-gov.kuleuven.ezproxy.kuleuven.be/pmc/articl...
9 van 23 10/02/2016 9:19
23. Cauchon E., Falgueyret J. P., Auger A., Melnyk R. A. (2011) A high throughput continuous assay for
screening and characterization of inhibitors of HIV reverse-transcriptase DNA polymerase activity. J.
Biomol. Screen. 16, 518–524 [PubMed: 21474837]
24. Götte M., Maier G., Onori A. M., Cellai L., Wainberg M. A., Heumann H. (1999) Temporal
coordination between initiation of HIV (+)-strand DNA synthesis and primer removal. J. Biol. Chem. 274,
11159–11169 [PubMed: 10196201]
25. Huang H., Chopra R., Verdine G. L., Harrison S. C. (1998) Structure of a covalently trapped catalytic
complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282, 1669–1675
[PubMed: 9831551]
26. Ehteshami M., Götte M. (2008) Effects of mutations in the connection and RNase H domains of HIV-1
reverse transcriptase on drug susceptibility. AIDS Rev. 10, 224–235 [PubMed: 19092978]
27. van Maarseveen N. M., Huigen M. C., de Jong D, Smits AM, Boucher CA, Nijhuis M. (2006) A novel
real time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse
transcriptase variants. J. Virol. Methods 133, 185–194 [PubMed: 16368153]
28. Boucher C. A., Keulen W., van Bommel T., Nijhuis M., de Jong D., de Jong M. D., Schipper P., Back N.
K. (1996) Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant
viruses generated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 40,
2404–2409 [PMCID: PMC163542] [PubMed: 8891152]
29. Smith A. J., Meyer P. R., Asthana D., Ashman M. R., Scott W. A. (2005) Intracellular substrates for the
primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and
quantitation in extracts from quiescent- and activated-lymphocyte subpopulations. Antimicrob. Agents
Chemother. 49, 1761–1769 [PMCID: PMC1087649] [PubMed: 15855493]
30. Meyer P. R., Matsuura S. E., Tolun A. A., Pfeifer I., So A. G., Mellors J. W., Scott W. A. (2002) Effects
of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer
unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother.
46, 1540–1545 [PMCID: PMC127181] [PubMed: 11959594]
31. Ray A. S., Murakami E., Basavapathruni A., Vaccaro J. A., Ulrich D., Chu C. K., Schinazi R. F.,
Anderson K. S. (2003) Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1
reverse transcriptase using a transient kinetic analysis. Biochemistry 42, 8831–8841 [PubMed: 12873144]
32. Sarafianos S. G., Clark A. D., Jr., Das K., Tuske S., Birktoft J. J., Ilankumaran P., Ramesha A. R., Sayer
J. M., Jerina D. M., Boyer P. L., Hughes S. H., Arnold E. (2002) Structures of HIV-1 reverse transcriptase
with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21, 6614–6624
[PMCID: PMC136941] [PubMed: 12456667]
33. Boyer P. L., Sarafianos S. G., Arnold E., Hughes S. H. (2001) Selective excision of AZTMP by
drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75, 4832–4842
[PMCID: PMC114238] [PubMed: 11312355]
34. Goldschmidt V., Marquet R. (2004) Primer unblocking by HIV-1 reverse transcriptase and resistance to
nucleoside RT inhibitors (NRTIs). Int. J. Biochem. Cell Biol. 36, 1687–1705 [PubMed: 15183338]
35. Meyer P. R., Matsuura S. E., So A. G., Scott W. A. (1998) Unblocking of chain-terminated primer by
HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 95,
13471–13476 [PMCID: PMC24843] [PubMed: 9811824]
36. Mathiesen S., Dam E., Roge B., Joergensen L. B., Laursen A. L., Gerstoft J., Clavel F. (2007)
Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine
and lamivudine in HIV-1. Antivir. Ther. 12, 335–343 [PubMed: 17591023]
37. Kisic M., Matamoros T., Nevot M., Mendieta J., Martinez-Picado J., Martínez M. A., Menéndez-Arias
L. (2011) Thymidine analogue excision and discrimination modulated by mutational complexes, including
Formation of a Quaternary Complex of HIV-1 Reverse Transcriptase wit... http://www-ncbi-nlm-nih-gov.kuleuven.ezproxy.kuleuven.be/pmc/articl...
10 van 23 10/02/2016 9:19
single amino acid deletions of Asp-67 or Thr-69 in HIV-1 reverse transcriptase. J. Biol. Chem. 286,
20615–20624 [PMCID: PMC3121480] [PubMed: 21504903]
38. Bradshaw D., Malik S., Booth C., Van Houtte M., Pattery T., Waters A., Ainsworth J., Geretti A. M.
(2007) Novel drug resistance pattern associated with the mutations K70G and M184V in human
immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 51, 4489–4491
[PMCID: PMC2167988] [PubMed: 17876005]
39. Hammond J. L., Koontz D. L., Bazmi H. Z., Beadle J. R., Hostetler S. E., Kini G. D., Aldern K. A.,
Richman D. D., Hostetler K. Y., Mellors J. W. (2001) Alkylglycerol prodrugs of phosphonoformate are
potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for
resistance mutations that suppress zidovudine resistance. Antimicrob. Agents Chemother. 45, 1621–1628
[PMCID: PMC90523] [PubMed: 11353603]
40. Mellors J. W., Bazmi H. Z., Schinazi R. F., Roy B. M., Hsiou Y., Arnold E., Weir J., Mayers D. L. (1995)
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to
foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39, 1087–1092
[PMCID: PMC162688] [PubMed: 7542860]
41. Meyer P. R., Lennerstrand J., Matsuura S. E., Larder B. A., Scott W. A. (2003) Effects of dipeptide
insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on
primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J. Virol. 77,
3871–3877 [PMCID: PMC149510] [PubMed: 12610164]
42. Tachedjian G., Hooker D. J., Gurusinghe A. D., Bazmi H., Deacon N. J., Mellors J., Birch C., Mills J.
(1995) Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology
212, 58–68 [PubMed: 7545854]
43. Cases-Gonzalez C. E., Gutierrez-Rivas M., Ménendez-Arias L. (2000) Coupling ribose selection to
fidelity of DNA synthesis. The role of Tyr-115 of human immunodeficiency virus type 1 reverse
transcriptase. J. Biol. Chem. 275, 19759–19767 [PubMed: 10748215]
44. Gao G., Orlova M., Georgiadis M. M., Hendrickson W. A., Goff S. P. (1997) Conferring RNA
polymerase activity to a DNA polymerase: a single residue in reverse transcriptase controls substrate
selection. Proc. Natl. Acad. Sci. U.S.A. 94, 407–411 [PMCID: PMC19524] [PubMed: 9012795]
45. Auger A., Beilhartz G. L., Zhu S., Cauchon E., Falgueyret J. P., Grobler J. A., Ehteshami M., Götte M.,
Melnyk R. A. (2011) Impact of primer-induced conformational dynamics of HIV-1 reverse transcriptase on
polymerase translocation and inhibition. J. Biol. Chem. 286, 29575–29583 [PMCID: PMC3190998]
[PubMed: 21737446]
46. Sarafianos S. G., Das K., Ding J., Boyer P. L., Hughes S. H., Arnold E. (1999) Touching the heart of
HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem. Biol. 6,
R137–R146 [PubMed: 10322129]
47. Zahn K. E., Tchesnokov E. P., Götte M., Doublié S. (2011) Phosphonoformic acid inhibits viral
replication by trapping the closed form of the DNA polymerase. J. Biol. Chem. 286, 25246–25255
[PMCID: PMC3137095] [PubMed: 21566148]
48. Scarth B., McCormick S., Götte M. (2011) Effects of mutations F61A and A62V in the fingers
subdomain of HIV-1 reverse transcriptase on the translocational equilibrium. J. Mol. Biol. 405, 349–360
[PubMed: 21056575]
Figures and Tables
Formation of a Quaternary Complex of HIV-1 Reverse Transcriptase wit... http://www-ncbi-nlm-nih-gov.kuleuven.ezproxy.kuleuven.be/pmc/articl...
11 van 23 10/02/2016 9:19
FIGURE 1.
Chemical structure of INDOPY-1. 5-Methyl-1-(4-nitrophenyl)-2-oxo-2,5-dihydro-1H-pyrido[3,2-b]indole-3-carbonitrile.
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FIGURE 2.
Effect of ATP on INDOPY-1-mediated inhibition of RT. A, single nucleotide incorporation was monitored with increasing
concentrations of INDOPY-1 in the presence of different ATP levels. Changes in IC  values for INDOPY-1 as a function of
ATP concentration are shown in the graph (n = 3). B, multiple nucleotide incorporation was monitored over time on a
heteropolymeric RNA template. The assay was repeated in the presence of 10 µM dNTP mix, 6 µM INDOPY-1, as well as 3
mM ATP, UTP, GTP, or CTP. Reduction in full-length product formation is indicative of inhibition.
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FIGURE 3.
Effect of ATP derivative compounds on INDOPY-1-mediated inhibition of RT. A, multiple nucleotide incorporation was
monitored over time on a homopolymeric template. DNA synthesis inhibition was monitored in the presence of 10 µM
INDOPY-1 alone or with 1 mM ATP or benzimidazole-riboside-TP. B, time course assays were repeated for a total of 13 ATP
derivatives (chemical structures are provided in supplemental Fig. 1). Amount of DNA product formed at 10 min in the
presence of 1 mM ATP derivative and 10 µM INDOPY-1 was quantified and normalized to the amount of DNA product
formed at 10 min in the presence of INDOPY-1 alone. Control bar represents normalized product formed in the presence of
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10 µM INDOPY-1. Clear bars represent ATP derivatives with modifications to the base moiety. Gray bars represent ATP
derivatives with modified sugar moieties, and black bars represent ATP derivatives with modified phosphate moieties. Most
ATP derivatives were tested in two to three separate experiments.
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FIGURE 4.
Effect of ATP on stabilization of RT·DNA·DNA· INDOPY-1 complex. A, band shift experiment was performed on a
DNA·DNA substrate. Conditions were optimized for an unstable binary complex (lane 0). As INDOPY-1 concentrations
increase, a stable ternary complex is formed, as indicated by the observed shift. The band shift experiment was repeated in the
presence of 2 mM ATP. The absence of a significant amount of complex formed in the 0 lane indicates that in the absence of
INDOPY-1 ATP does not stabilize the complex. B, amount of complex formed was plotted as a function of INDOPY-1
concentration. Apparent K  value for INDOPY-1 is 216.5 nM in the absence of ATP and 15.4 nM with ATP.d
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TABLE 1
MT-2 cell-based EC  values for INDOPY-1
Virus AZT INDOPY-1 PFA
EC FC EC FC EC FC
µM µM µM
WT 32.6 ± 10.1 54.5 ± 4.7 17.6 ± 7.4
TAM1 180.6 ± 62.9 5.5 110.9 ± 8.3 2.0 7.9 ± 4.5 0.5
TAM2 130.9 ± 39.7 4.0 262.3 ± 76.7 4.8 10.5 ± 0.1 0.6
Remodeled TAMs 36.0 ± 20.6 1.1 9.4 ± 2.0 0.2 112.3 ± 7.8 6.4
 Reported values are based on three separate experiments.
 Half-maximal effective concentration (EC ) refers to the inhibitor concentration at which virus
replication is reduced by 50% in cell culture assays.
 Fold-change (FC) values were obtained by dividing the EC  value of each inhibitor for mutant RT with
the corresponding EC  value for WT RT.
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FIGURE 5.
DNA synthesis inhibition by PFA. RT mutants were evaluated for sensitivity to PFA. Each RT mutant was incubated with 1
µM dNTP mix and increasing concentrations of PFA for 10 min at 37 °C. Full-length DNA synthesis was visualized on 12%
denaturing polyacrylamide gels. In the absence of magnesium, no polymerization is observed in control lanes.
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FIGURE 6.
ATP-mediated excision of AZT-MP and rescue of DNA synthesis. DNA·DNA primer· template substrate was incubated
with an excess of RT (WT or mutant) and 10 µM AZP-TP in the presence of 0.5 µM dNTPs and 3.5 mM ATP. DNA synthesis
and rescue was initiated with the addition of MgCl  and monitored at various time points up to 90 min. In the absence of
magnesium, no polymerization is observed in control lanes.
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TABLE 2
In vitro IC  values for INDOPY-1 in the presence of increasing ATP
ATP IC
WT Remodeled TAMs FC
mM nM
0 76.3 ± 28.3 52.0 ± 24.3 0.7
0.1 56.7 ± 30.6 22.0 ± 23.3 0.4
0.3 26.3 ± 12.9 3.4 ± 0.8 0.1
1 10.7 ± 7.4 3.6 ± 2.4 0.3
 Reported values are based on three separate experiments.
 In vitro half-maximal inhibitory concentration (IC ) values were measured using a Quench FRET assay.
Because of the experimental setup, namely reduced RT concentrations, the IC  values reported here
appear lower than ones reported in Fig. 2A.
 Fold-change (FC) values were obtained by dividing the IC  value of INDOPY-1 for remodeled TAMs
enzyme with that of WT RT for each corresponding ATP concentration.
50
50
,
a b
c
a
b
50
50
c
50
Formation of a Quaternary Complex of HIV-1 Reverse Transcriptase wit... http://www-ncbi-nlm-nih-gov.kuleuven.ezproxy.kuleuven.be/pmc/articl...
20 van 23 10/02/2016 9:19
FIGURE 7.
Effect of INDOPY-1 and ATP on enzyme translocation. A, 5′-labeled nucleic acid substrate was incubated with an excess
of enzyme in the presence of increasing concentrations of INDOPY-1. In the absence of INDOPY-1, the complex shows a
bias toward pre-translocation (lanes 0). The DNA template was subsequently cleaved with the addition of Fe  in the
presence or absence of 1 mM ATP. The site of DNA cleavage is indicated on the template sequence with arrows. B, amount of
enzyme in the pre-translocated state was plotted as function of INDOPY-1 concentration.
2+
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FIGURE 8.
In silico modeling of INDOPY-1 and ATP at the polymerase active site. A, INDOPY-1 is colored in red; HIV-1 RT is
colored in yellow, and the DNA hybrid is colored in gray. B, position of dTTP (cyan) from the 1RTD crystal structure was
overlaid with the docking pose of INDOPY-1 (red). Shown in red are the residues associated with INDOPY-1 resistance
(Tyr-115 and Met-184). C, ATP was docked to the model containing INDOPY-1. The top view of the surface map of HIV-1
RT is shown with focus on the cavity to which ATP (white) binds when INDOPY-1 (red) is located at the nucleotide-binding
site. D, side view of the surface map of HIV-1 RT, highlighting the effect of ATP that prevents INDOPY-1 from dissociating
from the RT active site. E, dashed lines are shown indicating putative interactions between the critical amino group of
adenine base of ATP, the protein and the nucleic acid substrate; the phosphate backbone for the ultimate and penultimate
positions in the primer, as well as the terminal amide of the Gln-242 side chain, are located within 5  of the amino group.
Residues that result in hypersusceptibility to INDOPY-1 are shown in green.
Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry
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